What this is
- How it works
- How it works isn't classified yet
- Tested for
- Primary Gout and Hyperuricemia
- Main trialPhase 2
- “SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg/d febuxostat tablet in reducing uric acid in subjects with primary gout and hyperuricemia The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and 40 mg/d febuxostat compared with 60 mg/d febuxostat in primary gout and hyperuricemia subjects with inadequate control on 40 mg/d febuxostat for 12 weeks.”In the company’s words, NCT07362355 on ClinicalTrials.gov
Other drugs for Primary Gout and Hyperuricemia
- DapansutrileOlatec Therapeutics, Inc. · Phase 2/3
- Combined metabolic activatorsScandiBio Therapeutics AB · Phase 3
- DotinuradCrystalys Therapeutics · Phase 3
- AR882Arthrosi Therapeutics · Phase 2
- PRX-115Protalix · Phase 2
- BR2251BioRay Pharmaceutical Co., Ltd. · Phase 2
Coming up1
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Jul 2027 | The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | |
| Phase 3Completed | 14 Jul 2021 | A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout | |
| Phase 3Completed | 13 Dec 2023 | A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout | |
| Phase 2Unknown | 30 May 2023 | Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | |
| Phase 1Completed | 5 Sep 2021 | Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control) | |
| Phase 1Unknown | Dec 2022 | Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment | |
| Phase 1Completed | 13 Jan 2024 | Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects | |
| Phase 1Completed | 1 Jul 2024 | Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026